Business
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (“Company”) (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies
About this update from Pharmacyte Biotech, Inc.
[{"type":"text","content":" LAGUNA HILLS, Calif.--(BUSINESS WIRE)--\nPharmaCyte Biotech, Inc. (“Company”) (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box® , announced today that its 2021 Annual Meeting of Stockholders, held on June 16, 2021, has been adjourned until June 30, 2021, at 11:00 a.m. Pacific Daylight Time. The meeting was adjourned in order to allow additional time for stockholders to vote on Proposal No. 2, the proposal to increase the authorized number of shares of capital stock. The other proposals in the Company’s Proxy Statement received enough votes to pass.\n\nWhen the annual meeting is reconvened on June 30, 2021, it will continue to be held virtually at www.virtualshareholdermeeting.com/PMCB2021.\n\nThe Company’s Chief Executive Officer, Kenneth L. Waggoner, stated that, “Passage of Proposal No. 2 is critical for the Company to remain viable and for its pancreatic cancer therapy to remain in development and avoid being shelved. Without an increase in its authorized shares of common stock, the Company will be unable to continue to finance itself and its development programs, and it will likely have to cease operations. We encourage every shareholder to obtain and read the Proxy Statement and then participate in the vote. Over 49% of the outstanding shares has voted in favor of Proposal No. 2; however, more than 50% is required for passage.”\n\nTo listen to the Company’s shareholder meeting that took place on June 16, 2021, click this link: www.virtualshareholdermeeting.com/PMCB2021.\n\nTo learn more about the Company’s pancreatic cancer therapy and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the Company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer.\n\nAbout PharmaCyte Biotech\n\nPharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.\n\nPharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells th...